Pharsight

1. List of Bethkis drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939502	CHIESI	Optimised formulation of tobramycin for aerosolization	Jun, 2022 (7 months ago)
US6987094	CHIESI	Optimized formulation of tobramycin for aerosolization	Sep, 2022 (4 months ago)
US7696178	CHIESI	Optimised formulation of tobramycin for aerosolization	Sep, 2022 (4 months ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: Management of cystic fibrosis patients

Dosage: SOLUTION;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg/4 mL	31 Aug, 2017	1	26 Jun, 2019	22 Sep, 2022	Eligible

Strength	Dosage	Availability
300MG/4ML	SOLUTION;INHALATION	Prescription

2. List of Cardene drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US10758616	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (4 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (4 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/mL, 10 mL Ampoules	27 Dec, 2006	1
0.1 mg/mL, 200 mL 0.2mg/mL, 200 mL	09 Jan, 2013	1		26 Dec, 2027

Strength	Dosage	Availability
25MG/10ML (2.5MG/ML)	INJECTABLE;INJECTION	Discontinued
40MG/200ML (0.2MG/ML)	INJECTABLE;INTRAVENOUS	Discontinued
20MG/200ML (0.1MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

3. List of Cleviprex drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (8 years from now)
US10010537	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (8 years from now)
US8658676	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (8 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/50 mL and 50 mg/100 mL	02 Jul, 2019	1		10 Oct, 2031

Strength	Dosage	Availability
25MG/50ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Prescription
50MG/100ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Prescription
125MG/250ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Discontinued

4. List of Ferriprox drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156	CHIESI	Liquid formulation for deferiprone with palatable taste	Oct, 2029 (6 years from now)
US10940115	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (15 years from now)
US10780055	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (15 years from now)
US10940116	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (15 years from now)
US11357731	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (15 years from now)
US11458103	CHIESI	Delayed release deferiprone tablets and methods of using the same	Oct, 2038 (15 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Apr 30, 2024

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 09 September, 2015

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
80MG/ML	SOLUTION;ORAL	Discontinued
100MG/ML	SOLUTION;ORAL	Prescription

5. List of Kengreal drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6130208	CHIESI	Formulation containing a nucleotide analogue	Jun, 2023 (4 months from now)
US9925265	CHIESI	Methods of treating or preventing stent thrombosis	May, 2029 (6 years from now)
US9427448	CHIESI	Methods of treating, reducing the incidence of, and/or preventing ischemic events	Nov, 2030 (7 years from now)
US8680052	CHIESI	Methods of treating, reducing the incidence of, and/or preventing ischemic events	Mar, 2033 (10 years from now)
US9439921	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US9700575	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US9295687	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US10039780	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor; Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion; Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci; Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method

Dosage: POWDER;INTRAVENOUS